June 4, 2015
Contact: Carol McKay, NCL, 412-945-3242, email@example.com
Washington, DC—The National Consumers League (NCL), the nation’s pioneering consumer advocacy organization, which has championed women’s health and gender equity, is applauding today’s 18-6 vote of the U.S. Food and Drug Administration advisory committee to recommend to the agency’s approval of the drug flibanserin for low libido in women, or female sexual dysfunction (FSD). The most common FSD condition is loss of sex drive, or HSDD.
The FDA generally accepts the recommendations of its advisory committee, but that formal decision will come in August.
The following statement may be attributed to Sally Greenberg, NCL executive director:
“At present there are no FDA-approved drugs to treat FSD, whereas there are 26 drugs to treat male sexual dysfunction. We welcome the positive recommendation of the FDA advisory committee. We urge the FDA to approve this treatment quickly, begin the process to address the long-overdue void that exists, and allow women who suffer from HSDD to finally get access to this important medication.”
About the National Consumers League
The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit www.nclnet.org.